CHOP Names Stella Chou Permanent Hematology Chief After Interim Stint
Event summary
- Stella T. Chou, MD, transitions from interim to permanent Chief of Hematology at CHOP effective July 1, 2026.
- Dr. Chou's research focuses on sickle cell disease, transfusion medicine, and synthetic blood products.
- CHOP's hematology program is one of the largest in the U.S., offering FDA-approved gene therapies for thalassemia and sickle cell disease.
The big picture
CHOP's appointment of Dr. Chou as permanent Chief of Hematology solidifies its position as a leader in pediatric hematology research and treatment. Her expertise in sickle cell disease and transfusion medicine aligns with the growing demand for advanced, personalized therapies in rare blood disorders. The move underscores CHOP's commitment to translational science and its role in shaping national clinical guidelines.
What we're watching
- Research Leadership
- How Dr. Chou's focus on personalized transfusion and synthetic blood products will accelerate CHOP's position in pediatric hematology.
- Industry Collaboration
- Whether CHOP can sustain its leadership role through partnerships with ASH and AABB under Dr. Chou's guidance.
- Regulatory Approvals
- The pace at which CHOP advances FDA-approved gene therapies for rare blood disorders under new leadership.
Related topics